InsiderTrades.com logo
Anne Evans Kingston net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Anne Kingston Biography and Net Worth

Insider of Prothena

Annie E. Kingston has served as our Chief Strategy Officer since April 2026. Ms. Kingston served as Vice President, Corporate Strategy and Chief of Staff from March 2025 to April 2026. Prior to joining Prothena in April 2023, Ms. Kingston held several roles of increasing responsibility at ClearView Healthcare Partners (a life sciences strategy consultancy), where she advised pharmaceutical and biotechnology companies on both product-level and corporate strategy from 2017 to 2023, including as an Associate Principal and Project Leader. Prior to that role, Ms. Kingston was a consultant at The Dedham Group. Ms. Kingston earned her B.A. in Biology and Psychology from Fairfield University.

What is Anne Evans Kingston's net worth?

The estimated net worth of Anne Evans Kingston is at least $452.95 thousand as of July 29th, 2026. Kingston owns 55,782 shares of Prothena stock worth more than $452,950 as of July 31st. This net worth estimate does not reflect any other investments that Kingston may own. Learn More about Anne Evans Kingston's net worth.

How do I contact Anne Evans Kingston?

The corporate mailing address for Kingston and other Prothena executives is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. Prothena can also be reached via phone at (531) 236-2500 and via email at [email protected]. Learn More on Anne Evans Kingston's contact information.

Has Anne Evans Kingston been buying or selling shares of Prothena?

During the past quarter, Anne Evans Kingston has sold $64,897.14 of Prothena stock. Most recently, Anne Evans Kingston sold 7,662 shares of the business's stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $8.47, for a transaction totalling $64,897.14. Following the completion of the sale, the insider now directly owns 55,782 shares of the company's stock, valued at $472,473.54. Learn More on Anne Evans Kingston's trading history.

Who are Prothena's active insiders?

Prothena's insider roster includes Christopher Henney (Director), Michael Isaacs (General Counsel), Carol Karp (Insider), Anne Kingston (Insider), Gene Kinney (Pres), Michael Malecek (Insider), Tran Nguyen (CFO & Chief Strategy Officer ), Dennis Selkoe (Director), Brandon Smith (COO), Karin Walker (CAO), and Wagner Zago (Insider). Learn More on Prothena's active insiders.

Are insiders buying or selling shares of Prothena?

During the last twelve months, Prothena insiders bought shares 5 times. They purchased a total of 345,000 shares worth more than $3,097,250.00. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 16,048 shares worth more than $135,926.56. The most recent insider tranaction occured on July, 29th when insider Anne Evans Kingston sold 7,662 shares worth more than $64,897.14. Insiders at Prothena own 10.4% of the company. Learn More about insider trades at Prothena.

Information on this page was last updated on 7/29/2026.

Anne Evans Kingston Insider Trading History at Prothena

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/29/2026Sell7,662$8.47$64,897.1455,782View SEC Filing Icon  
See Full Table

Anne Evans Kingston Buying and Selling Activity at Prothena

This chart shows Anne Evans Kingston's buying and selling at Prothena by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Prothena Company Overview

Prothena logo
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Read More

Today's Range

Now: $8.12
Low: $8.00
High: $8.51

50 Day Range

MA: $9.09
Low: $7.91
High: $10.18

2 Week Range

Now: $8.12
Low: $6.61
High: $11.80

Volume

545,490 shs

Average Volume

529,947 shs

Market Capitalization

$425.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A